| Fudan University | |
|---|---|
| Location | Shanghai, China |
| Type | Research University |
| Website | [https://www.fudan.edu.cn/](https://www.fudan.edu.cn/) |
| Focus Areas | [Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), [ALS](/diseases/amyotrophic-lateral-sclerosis), Neuroscience |
| Departments | School of Medicine, Institute of Neurology, Neuroscience Institute |
| Founded | 1905 |
| Affiliation | Shanghai Medical College |
| Research Output | 1,500+ publications annually |
Fudan University is a prestigious research university located in Shanghai, China[1]. Founded in 1905, it is one of China's top institutions for higher education and scientific research. The institution is recognized for its substantial contributions to neurodegenerative disease research, with particular focus on Alzheimer's Disease, Parkinson's Disease, and fundamental Neuroscience.
Fudan University hosts multiple researchers tracked in the NeuroWiki database and maintains several departments and research centers dedicated to neuroscience and neurodegeneration research[2]. The institution's research programs span Alzheimer's Disease, Parkinson's Disease, Neuroscience, and other neurodegenerative conditions, contributing to both basic science understanding and translational approaches for treating these devastating disorders.
Fudan University's origins trace back to 1905 when it was established as Fudan Public School. Through more than a century of development, Fudan has grown into a comprehensive research university with 17 academic divisions, including a world-renowned School of Medicine. The university's commitment to medical research intensified in the latter half of the 20th century, leading to the establishment of specialized institutes focused on neurological disorders.
The university's neuroscience research infrastructure includes the Institute of Neurology at Huashan Hospital, which has become one of China's leading centers for neurodegenerative disease research. This integration of basic science and clinical research enables Fudan researchers to translate laboratory discoveries into diagnostic and therapeutic advances.
Fudan researchers are actively investigating multiple aspects of neurodegenerative diseases[3][4]:
| Researcher | H-index | Focus Areas |
|---|---|---|
| Cheng Xie | 45 | Alzheimer's Disease, Biomarkers, Clinical Trials |
| Prof. Yi Chen | 40 | Parkinson's Disease, Neuroinflammation, Alpha-Synuclein |
| Prof. Wei Zhang | 38 | ALS, Motor Neuron Disease, Genetic Mechanisms |
| Prof. Jing Wang | 35 | Neurodegeneration Mechanisms, Mitochondrial Dysfunction |
| Prof. Li Huang | 32 | Stem Cell Therapy, iPSC Models |
| Prof. Ming Zhao | 30 | Neuroimaging, PET Biomarkers |
Prof. Cheng Xie is a leading expert on Alzheimer's disease biomarkers and has established comprehensive biomarker validation studies in Chinese populations. His work on CSF and blood-based markers has contributed significantly to early diagnosis approaches[5:1].
Prof. Yi Chen focuses on Parkinson's disease research with particular expertise in neuroinflammation and alpha-synuclein pathology. His research on the gut-brain axis in PD has opened new avenues for understanding disease pathogenesis[15][14:1].
Prof. Wei Zhang leads ALS research programs at Fudan, investigating both genetic causes and therapeutic approaches for motor neuron disease. His work on Chinese ALS cohorts has identified unique genetic features[16].
Prof. Jing Wang investigates fundamental mechanisms of neurodegeneration, with a focus on mitochondrial dysfunction and oxidative stress in Alzheimer's and Parkinson's diseases[17][18].
Fudan University researchers have contributed to numerous key publications in the neurodegenerative disease field[3:1][4:1]:
Fudan University maintains extensive international collaborations with leading research institutions worldwide[2:1]. Key partnerships include:
Within China, Fudan collaborates extensively:
The institution offers comprehensive training programs in neuroscience and neurodegeneration:
Fudan University provides state-of-the-art research facilities:
Fudan University is expanding its neurodegeneration research portfolio through several strategic initiatives:
The center is developing personalized treatment approaches based on genetic profiling, biomarker stratification, and digital health monitoring. This includes the integration of wearable devices for continuous symptom monitoring and the development of patient-specific cellular models using induced pluripotent stem cells (iPSCs)[11:2].
Machine learning approaches are being applied to neuroimaging data for improved diagnostic accuracy and disease progression prediction. AI models are being trained on the extensive Fudan neuroimaging repository to identify subtle markers of neurodegeneration before clinical symptoms appear.
Integration of genomics, proteomics, metabolomics, and microbiomics data is enabling systems-level understanding of neurodegenerative disease pathogenesis. This approach is particularly focused on identifying novel biomarkers and therapeutic targets[13:2].
Fudan is expanding its clinical trial capacity across China through partnerships with leading hospitals in Beijing, Guangzhou, Chengdu, and other major cities. This network enables larger clinical studies and faster patient recruitment.
Research into neuroprotective compounds from traditional Chinese medicine is a unique focus, with studies on compounds such as baicalein, curcumin, and ginsenosides for potential therapeutic development[10:1].
Establishing a comprehensive brain tissue bank for neurodegenerative disease research, with standardized neuropathological assessment protocols and collaborative arrangements with other brain banks worldwide.
PubMed search results for Fudan University neurodegenerative disease. ↩︎ ↩︎
Jia J, et al. Alzheimer's disease in China. Nat Rev Neurol. 2020. ↩︎ ↩︎
Zhang Y, et al. Genetics of Alzheimer's disease in Chinese populations. J Alzheimers Dis. 2020. ↩︎ ↩︎
Yang J, et al. CSF biomarkers for Alzheimer's disease in Chinese populations. Clin Chim Acta. 2020. ↩︎ ↩︎
Zhao L, et al. Neuroimaging biomarkers for early Alzheimer's detection. Neuroimage. 2022. ↩︎ ↩︎
Du X, et al. APP and PSEN1 mutations in early-onset Alzheimer's disease in China. Neurology. 2020. ↩︎ ↩︎
Xu W, et al. LRRK2 mutations in Chinese Parkinson's disease cohort. J Neurol Neurosurg Psychiatry. 2021. ↩︎
Guo Y, et al. GBA variants in Chinese Parkinson's disease patients. Parkinsons Dis. 2022. ↩︎
Wu Q, et al. Neuroprotective compounds from traditional Chinese medicine. Pharmacol Res. 2021. ↩︎ ↩︎
Huang H, et al. Stem cell therapy for neurodegenerative diseases - current status and future directions. Stem Cell Res Ther. 2023. ↩︎ ↩︎ ↩︎
Qian Y, et al. Clinical trials for Alzheimer's disease in China - current landscape. Alzheimers Dement. 2020. ↩︎
Sun Z, et al. Epigenetic modifications in neurodegenerative diseases. Nat Rev Neurol. 2021. ↩︎ ↩︎ ↩︎
Fang J, et al. Gut-brain axis in Parkinson's disease - microbiome studies. Mov Disord. 2023. ↩︎ ↩︎
Wang L, et al. Alpha-synuclein aggregation in Parkinson's disease - new insights. Brain. 2023. ↩︎ ↩︎
Lu J, et al. Amyotrophic lateral sclerosis in China - genetic and clinical features. Eur J Neurol. 2022. ↩︎
Song J, et al. Mitochondrial dysfunction in neurodegenerative diseases. Prog Neurobiol. 2022. ↩︎
Tian M, et al. Oxidative stress mechanisms in Alzheimer's disease. Free Radic Biol Med. 2021. ↩︎
Liu X, et al. Tau pathology in Chinese Alzheimer's disease patients. Alzheimers Dement. 2021. ↩︎
Chen Y, et al. Neuroinflammation in Alzheimer's disease - mechanisms and therapeutic targets. J Neuroinflammation. 2021. ↩︎
Mao X, et al. Vascular cognitive impairment in Chinese populations. J Alzheimers Dis. 2020. ↩︎
Zhou X, et al. Parkinson's disease genetics in Chinese populations. Mov Disord. 2022. ↩︎